Heart failure with preserved ejection fraction remains challenging to diagnose, with limited therapies that enhance survival despite addressing comorbidities.
Absolute Event Rate: 0% vs 0%
Heart failure with preserved ejection fraction (HFpEF) includes almost half of heart failure cases typified by a specific clinical syndrome. Despite diagnostic and management advances, HFpEF still presents a diagnostic challenge and a paucity of therapies specifically aimed at enhancing survival and improving quality of life is still lacking. This review elucidates the diagnostic complexity of HFpEF, highlighting the use of both subjective and objective criteria within algorithmic frameworks. It also examines the significant impact of comorbidities on the progression of HFpEF. Additionally, we explore the latest evidence on targeting these comorbidities therapeutically, although the benefits to mortality are still limited.
Shahid et al. (Fri,) reported a other. Heart failure with preserved ejection fraction remains challenging to diagnose, with limited therapies that enhance survival despite addressing comorbidities.